Real effectiveness data of Inavolisib in the treatment of breast cancer

Inavolisib (Inavolisib) is an oral PI3Kα selective inhibitor, mainly targeting patients with advanced or metastatic HRpositive /HER2negative breast cancer carrying PIK3CA mutations. In a number of international clinical trials, the drug has shown clear efficacy advantages when used in combination with standard endocrine therapy. Phase III clinical trial data (INAVO120 study) showed that inaliset significantly improved progression-free survival (PFS) and overall response rate (ORR), becoming a new hope for precision treatment of breast cancer.

In the INAVO120 trial, investigators evaluated the combination of inaliset and fulvestrant (fulvestrant) versus CDK4/6inhibitor palbociclib (palbociclib) in the treatment of PIK3CA mutated breast cancer. The results showed that the triple regimen achieved a median progression-free survival (PFS) of 15 months, while the control group was only 7.3 months, the hazard ratio (HR) was 0.52, indicating a 48% reduction in the risk of disease progression. In addition, the objective response rate (ORR) was significantly improved, reaching 42%, compared with 26% in the control group, showing a significant tumor shrinkage response.

It is worth noting that the efficacy of inalised is stable in multiple subgroups. Whether it is patients who have received CDK4/6 treatment before or those with visceral metastasis, the clinical benefits are obvious. The study also found that the drug has good activity in patients with brain metastases, providing new treatment possibilities for people who are currently difficult to treat. In addition, since Inarise targets PI3KAt the α mutation site, the treatment is more targeted and is expected to reduce the toxic effects on normal tissues and improve the tolerability of long-term medication.

Overall, inalise shows a high true effectiveness and good survival benefit in the treatment of PIK3CA mutated breast cancer patients, especially with better results under combination treatment strategies. As the drug is gradually launched globally, its status in the field of targeted treatment of breast cancer is expected to be further enhanced. In the future, we can also expect it to be combined with more new drugs to expand the scope of indications and bring more personalized and effective treatment options to breast cancer patients.

Reference materials:https://www.drugs.com/